← Leaderboards
Petros Giannikopoulos
University Of California Berkeley
$715,682
Attributed
$1,431,363
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $489.5K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,431,363 · 1
By mechanism
U01$1,431,363 · 1
Top collaborators
- Umut A. Gurkan3 shared
Most similar at University Of California Berkeley
Same institution · by research overlap
- Hei Sook Sul$25,068,703
- Song Li$16,504,735
- Arunava Majumdar$2,049,979
- Ross C Wilson$1,955,342
- Kevin Mark$174,334
Others in their field
Other Rising Stars on “Abnormal Red Blood Cell”
- Jenifer Gomez Pastora · Texas Tech University$587,878
- Wenjun Deng · Massachusetts General Hospital$522,065
- Ran An · Case Western Reserve University$425,944
- Karolyn Ann Oetjen · Washington University$341,896
- Biree Andemariam · New Health Sciences, Inc.$339,077
- Laurel Omert · New Health Sciences, Inc.$339,077
Research focus
Abnormal Red Blood CellAffectAlgorithm TrainingAmericanAssay DevelopmentAutosomeBase EditingBiochipBiophysical PropertiesBiophysicsBlood CapillariesCell PreparationCellsChemistryClinical DevelopmentClinically RelevantClinical TrialsCodeCohortDevicesDiagnosticDiagnostic AssayDiagnostic EquipmentAbnormal Hemoglobins
Grant awards (3)
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease$470,454
U01 · FY2025 · AI · contact PI
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease$471,367
U01 · FY2024 · AI · contact PI
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease$489,542
U01 · FY2023 · AI · contact PI